by The human immunoglobulin (pH4) for intravenous injection market is estimated to be valued at US$ 61.6 Bn in 2023 and is expected to exhibit a CAGR of 12 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Human immunoglobulin refers to a sterile, purified immunoglobulin solution manufactured from human plasma containing mainly immunoglobulins G (IgG) with trace amounts of IgA and IgM. It is a polyclonal antibody preparation used for several indications like primary immunodeficiencies, immune thrombocytopenia, Guillain-Barre Syndrome, etc. The human immunoglobulin (pH4) products provide standard protection against various infections due to their high antibody content and ready absorption.
Market Dynamics:
The global human immunoglobulin (pH4) for intravenous injection market is mainly driven by the increasing prevalence of neurological and immunodeficiency disorders. Neurological disorders are a leading cause of disability worldwide. As per the statistics provided by WHO, around 50 million people suffer from epilepsy worldwide. Similarly, the common variable immunodeficiency (CVID) affects 1 in every 25,000-50,000 individuals. In addition to this, factors like development of new recombinant therapies and government support in developed regions are also expected to boost market growth during the forecast period. However, high costs associated with manufacturing and stringent regulations for plasma-derived products may hamper market growth in developing regions.
SWOT Analysis
Strength: Human Immunoglobulin (pH4) for Intravenous Injection has strong therapeutic effects in treating various immunodeficiency and neurological disorders. It has a well established manufacturing process and satisfies the increasing demand for immunoglobulin therapy. The market is dominated by major players who have extensive resources to invest in R&D.
Weakness: manufacturing human immunoglobulin is an expensive and complex process which increases the production costs. Shortage of plasma collection centers and donors impacts the adequate supply of immunoglobulin.
Opportunity: Rising prevalence of immunodeficiency and neurological disorders drives the demand for immunoglobulin therapy. Increase in plasma collection centers especially in developing nations can help boost the supplies.
Threats: Stringent regulations surrounding plasma collection and manufacturing acts as a challenge. Rising competition from alternative therapies impacts the market growth.
Key Takeaways:
The Global Human Immunoglobulin (Ph4) For Intravenous Injection Market Demand is expected to witness high growth, exhibiting CAGR of 12% over the forecast period, due to increasing prevalence of neurological disorders and primary immunodeficiency diseases. Rise in plasma collection centers especially in Asia Pacific further supports market growth.
Regional analysis – North America dominates the global market and is expected to continue its dominance over the forecast period. This is attributed to growing patient awareness, continuing development of novel immunoglobulin therapies and strong reimbursement policies in the region. However, Asia Pacific is poised to lucrative growth owing to rising healthcare spending, rapid economic growth and increasing focus of major players to tap emerging markets.
Key players operating in the Human Immunoglobulin (pH4) for Intravenous Injection market are Takeda Pharmaceutical Company Limited, Baxter, CSL, Bayer AG, Grifols, S.A, Octapharma Brasil Ltda, Shanghai RAAS Blood Products Co Ltd, Hualan Biological Engineering, Inc, Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc), China Resources Boya Bio-pharmaceutical Group Co Ltd, ADMA Biologics, Inc, Sinopharm Group Co. Ltd. Major players are focused on strengthening their product portfolios through mergers, acquisitions and partnerships with plasma collectors.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
